{
    "nct_id": "NCT06500065",
    "official_title": "Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy",
    "inclusion_criteria": "* Patients >= 18 years of age\n* Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies\n* Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Hypersensitivity to somatostatin or similar peptides\n* Somatostatin long-acting analog in the past 6 months\n* Patients who are pregnant or lactating\n* Patients who are currently incarcerated\n* Patients with acute infections\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)\n* Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)",
    "miscellaneous_criteria": ""
}